An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin

There are no definitive data in humans on the dose dependence and/or cycle dependence of the pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD). This study examined the PK of PLD across a twofold dose variation and along 3 cycles. Fifteen patients received PLD in successive doses of 60, 30, and 45 mg/m2 (Arm A) and 30, 60, and 45 mg/m2 (Arm B… CONTINUE READING